Venture Funding and the NIH SBIR Program (2009) / Chapter Skim
Currently Skimming:
Appendix E: Analysis of the Evidence Submitted by BIO
Appendix E: Analysis of the Evidence Submitted by BIO
Pages 92-94
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 92... ...
SURVEYS BIO conducted telephone and Internet surveys of its "emerging company" membership -- defined as firms with fewer than 350 employees and no marketable products. A 2006 Internet survey indicated that 50 of 267 responding firms had been refused SBIR funding at NIH based on the venture capital exclusion.1 Of these, nine were able to find alternative funding.
|
From page 93... ...
As BIO claims, it also appears to be true that for five of the firms, the affected research did not involve their lead product. This raises questions about the likeli hood that this research would have led to any commercial result, if only because data from the NRC survey and NRC case studies indicates that such outcomes are less likely than commercialization of lead products.
|
From page 94... ...
About 18 percent of BIO respondents -- or 8 percent of BIO's emerging company membership -- reported that they had been excluded as a result of the SBA ruling, while about 2 percent of NRC respondents indicated that venture capital ownership was the primary cause of their non-ap plication to the program.4 Moreover, details of the surveys and the methodologies used for them have not been provided by BIO, so it is not possible to determine whether the survey process itself inadvertently introduced biases into the results. Conclusions.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.